Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Drug Profile

Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Alternative Names: Monoclonal antibodies against dengue - Visterra; VIS-513

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Massachusetts Institute of Technology; Visterra
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 18 Oct 2017 Visterra plans a phase I trial for VIS 513 for Dengue in 2018 (CTP#249894)
  • 05 Oct 2017 Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra is available for licensing as of 05 Oct 2017. www.visterrainc.com
  • 09 Sep 2015 VIS 513 licensed to Serum Institute of India in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top